Cytochrome P450 2C9 mediated metabolism in people with and without cancer

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 7, 2008, Pages 365-374

  Shord, S S ^a   Cavallari, L H ^a   Viana, M A G ^a   Momary, K ^a   Neceskas, J ^a   Molokie, R E ^b   Deyo, K ^a   Patel, S R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cancer; Cytochrome P450 enzymes; Cytokines; Drug metabolism; Genotype

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; OREGOVOMAB; PACLITAXEL; TOLBUTAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SEQUENCE; GENOTYPE; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEOPLASM; OVARY CANCER; POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

EID: 47549105549     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46365     Document Type: Article

References (34)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993; 44: 707-715.
2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004; 76: 113-118.
3. Ballester OF, Moscinski LC, Lyman GH, Chaney JV, Saba HI et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood. 1994; 83: 1903-1908.
4. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994; 55: 649-660.
5. Crommentuyn KM, Schellens JH, van den Berg JD, Beijnen JH. In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev. 1998; 24: 345-366.
6. Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999; 57: 951-954.
7. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev. 1996; 20: 52-56.
8. Galizia G, Lieto E, De Vita F, Romano C, Orditura M et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res. 2002a; 22: 473-482.
9. Galizia G, Orditura M, Romano C, Lieto E, Castellano P et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 2002b; 102: 169-178.
10. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000; 67: 32-43.
11. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996; 14: 2590-2611.
12. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets. 2006; 6: 295-311.
13. Hruska MW, Frye RF, Langaee TY. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem. 2004; 50: 2392-2395.
14. Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther. 2006; 80: 228-234.
15. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther. 2002; 72: 562-571.
16. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003; 43: 84-91.
17. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Molecular cancer therapeutics. 2004; 3: 363-371.
18. Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol. 2007; 5: 9-14.
19. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytocbrome P450 2C9. Methods Enzymol. 1996; 272: 139-145.
20. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology. 1995; 22: 1143-1153.
21. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet. 1992; 23: 132-146.
22. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and unducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004; 199: 193-209.
23. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002; 87: 277-280.
24. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006; 25: 1679-1691.
25. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80: 227-236.
26. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33 Suppl. 2003; 2: 23-30.
27. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003; 4: 224-232.
28. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002; 87: 21-27.
29. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther. 1990; 47: 403-411.
30. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet. 2003; 42: 1331-1357.
31. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994; 4: 171-184.
32. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol. 2000; 49: 485-488.
33. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54: 1257-1270.
34. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19: 1427-1432.